Core Viewpoint - The company "有棵树" is facing significant challenges in disclosing its Q3 2025 financial report due to shareholder disputes and management transitions, which have delayed the completion of asset and operational handovers [2][5][6]. Group 1: Financial Reporting Issues - The company announced that it could not disclose its Q3 2025 report by the legal deadline due to incomplete handover of financial documents and responsibilities from the previous management [2][7]. - The former chairman, 肖四清, provided the Q3 financial report on October 30, but the current board and management could not verify its accuracy due to missing necessary documentation [7][8]. - The company has been actively pursuing the completion of the handover process to ensure compliance with financial reporting requirements [5][6]. Group 2: Shareholder Disputes - The company is experiencing a power struggle between its former chairman 肖四清 and the current largest shareholder 王维, which has escalated into legal disputes [11][15]. - 王维, who holds 9.89% of the company's shares, and his associated entities have had their shares subject to judicial freezing due to ongoing litigation initiated by 肖四清 [13][14]. - Both parties are under investigation by the China Securities Regulatory Commission for failing to disclose significant information as required by law [18]. Group 3: Management Transition - The company has initiated a comprehensive takeover of its assets, business, finance, personnel, and locations, but the process has been hindered by the lack of cooperation from some members of the previous board and management [5][6]. - The seventh board of directors has been actively working to ensure that the previous management fulfills their handover obligations to facilitate the timely preparation and disclosure of the Q3 report [5][6].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 WINSHINE SCIENCE COMPANY LIMITED 瀛 晟 科 學 有 限 公 司 * ( 於百慕達註冊成立之有限公司 ) 傳真號碼 ： (852) 3162 6669 承董事會命 瀛晟科學有限公司 主席兼行政總裁 王敬渝 香港，二零二五年十月三十一日 於本公告日期，董事會由下列董事組成： (股份代號: 209) 更改總辦事處及香港主要營業地點、電話號碼及傳真號碼 瀛晟科學有限公司（「本公司」）董事會（「董事會」）謹此宣佈，自二零二五年十一月一 日起，本公司之總辦事處及香港主要營業地點、電話號碼及傳真號碼將更改如下： | 地址 | ： | 香港灣仔港灣道 | | 23 | 號 | | --- | --- | --- | --- | --- | --- | | | | 鷹君中心 15 | 樓 | 1501 | 室 | 電話號碼 ： (852) 3162 6666 執行董事： 王敬渝女士 胡欣綺女 ...

Group 1 - The company Ying Sheng Science (00209.HK) announced the resignation of Yu Yayin as the company secretary effective from October 17, 2025 [1] - Chen Yuyi has been appointed as the new company secretary and authorized representative under the Hong Kong Stock Exchange Listing Rule 3.05 [1] - The changes also include the appointment of Chen Yuyi as the authorized representative to receive legal documents and notices in Hong Kong as per the Companies Ordinance [1]

Core Points - Yingsheng Science (00209) announced the resignation of Yu Yayin as the company secretary effective from October 17, 2025 [1] - Chen Yuyi has been appointed as the new company secretary and authorized representative under the Hong Kong Listing Rules and relevant local laws [1] Summary by Category - **Management Changes** - Yu Yayin will resign from the position of company secretary and authorized representative [1] - Chen Yuyi has been appointed to replace Yu Yayin in these roles [1] - **Regulatory Compliance** - The changes comply with the Hong Kong Listing Rules and the Companies Ordinance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 WINSHINE SCIENCE COMPANY LIMITED 瀛 晟 科 學 有 限 公 司 * ( 於百慕達註冊成立之有限公司 ) (股份代號: 209) 1 (i) 余雅茵女士（「余女士」）辭任本公司之公司秘書（「公司秘書」）及不再擔任香港 聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 3.05 條項下之 授權代表及根據香港法例第 622 章公司條例第 16 部所規定代表本公司於香港接 收法律程序文件及通知書的本公司授權代表；及 (ii) 陳玉儀女士（「陳女士」）已獲委任為公司秘書及上市規則第 3.05 條項下之授權代 表及根據香港法例第 622 章公司條例第 16 部所規定代表本公司於香港接收法律 程序文件及通知書的本公司授權代表。 陳女士的履歷詳情載列如下： 陳女士，57 歲，持有澳洲 Monash University 商業法律碩士學位，並為香港公司治理公 會及英國特許公司治 ...

Core Viewpoint - Ying Sheng Science (00209) proposes a rights issue of 7 shares for every existing share held at a subscription price of HKD 0.14 per share, aiming to raise up to approximately HKD 182 million [1] Summary by Relevant Sections - **Rights Issue Details** - The company plans to issue up to approximately 1.3 billion rights shares, assuming no changes in the number of shares issued before the record date [1] - The subscription price represents a discount of about 23.5% compared to the closing price of HKD 0.183 per share on October 14, 2025 [1] - **Financial Implications** - If fully subscribed, the estimated net proceeds from the rights issue will be approximately HKD 176.5 million, assuming no changes in the number of shares issued before the record date [1]

Core Viewpoint - Ying Sheng Science (00209) announced a proposed rights issue, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share, aiming to raise up to approximately HKD 182 million [1] Group 1: Rights Issue Details - The company plans to issue up to approximately 1.3 billion rights shares, assuming no change in the number of shares issued as of the record date [1] - The subscription price represents a discount of about 23.5% compared to the closing price of HKD 0.183 per share on October 14, 2025 [1] - If fully subscribed, the estimated net proceeds from the rights issue will be approximately HKD 176.5 million, again assuming no change in the number of shares issued as of the record date [1]

Core Viewpoint - Ying Sheng Science (00209.HK) proposes a rights issue to raise up to approximately HKD 182 million by issuing up to 1,299,962,832 rights shares at a price of HKD 0.14 per share, representing a discount of about 23.5% from the last closing price of HKD 0.183 [1] Summary by Categories Rights Issue Details - The company plans to issue a maximum of 1,299,962,832 rights shares to eligible shareholders, with each existing share entitling the holder to one rights share [1] - The estimated net proceeds from the rights issue, assuming full subscription, will be approximately HKD 176.5 million [1] Use of Proceeds - Approximately HKD 116.6 million (about 66.0% of the net proceeds) is intended for loan repayment, covering both principal and interest [1] - About HKD 59.9 million (approximately 34.0% of the net proceeds) will be allocated for general working capital of the group [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示不會就本公告全部或任何部份內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 WINSHINE SCIENCE COMPANY LIMITED * 209 (1)建議按於記錄日期 每持有一(1)股現有股份獲發七(7)股供股股份的基準 以悉數包銷方式進行供股； (2)暫停辦理股份過戶登記手續；及 (3)委任獨立財務顧問 本公司財務顧問 建議供股 本公司建議按於記錄日期每持有一(1)股現有股份獲發七(7)股供股股份的基準，以認購 價每股供股股份0.14港元進行供股，以透過向合資格股東發行最多1,299,962,832股供 股股份（假設於記錄日期或之前已發行股份數目並無變動），籌集最多約182.0百萬港元 所得款項總額。 供股僅可提呈予合資格股東，且將不會向不合資格股東（如有）提呈。合資格股東有權 申請超出彼等於供股項下各自配額的供股股份。 假設供股獲悉數認購，則估計供股所得款項淨額將約為176.5百萬港元（假設於記錄日 ...

Group 1 - The company Ying Sheng Science (00209) announced that Mr. Weng Zu Tian will resign as the executive director and CEO effective October 14, 2025 [1] - Ms. Wang Jing Yu has been appointed as the new CEO while continuing her role as the executive director and chairman of the board [1] - Ms. Wang Yu Mei has resigned as an independent non-executive director and will no longer serve on the audit, remuneration, and nomination committees [1] - Mr. Wu Ji Wei has been appointed as an independent non-executive director and will serve on the audit, remuneration, and nomination committees [1]